scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1109828041 |
P356 | DOI | 10.1038/S41418-018-0228-Y |
P698 | PubMed publication ID | 30420758 |
P50 | author | Benjamin T. Kile | Q46040375 |
Daniel H Gray | Q48358835 | ||
Fernando Souza-Fonseca-Guimaraes | Q56783216 | ||
Nicholas D Huntington | Q59559817 | ||
Jai Rautela | Q88169955 | ||
P2093 | author name string | David Huang | |
Andrew M Lew | |||
Emma M Carrington | |||
David S Ritchie | |||
Mandy J Ludford-Menting | |||
Joanne E Davis | |||
Rachel Koldej | |||
Rebecca B Delconte | |||
Wilford Goh | |||
Yuhao Jiao | |||
P2860 | cites work | Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation | Q46848879 |
A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. | Q50967594 | ||
Antilymphocyte Globulin for Chronic Graft-versus-Host Disease | Q59281229 | ||
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes | Q59286691 | ||
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation | Q77658417 | ||
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice | Q28594052 | ||
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Q33438494 | ||
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). | Q34100754 | ||
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. | Q34184126 | ||
Acute Graft-versus-Host Disease: Novel Biological Insights | Q34497574 | ||
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
IL-15 availability conditions homeostasis of peripheral natural killer T cells | Q34807830 | ||
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial | Q34998580 | ||
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies | Q35083281 | ||
Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor | Q35546855 | ||
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism | Q36351357 | ||
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. | Q37272164 | ||
Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/- mice lacking macrophage Bcl-2. | Q37317950 | ||
Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model | Q37330859 | ||
Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease | Q37388077 | ||
One million haemopoietic stem-cell transplants: a retrospective observational study | Q38384271 | ||
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. | Q38650669 | ||
Graft-versus-host disease versus graft-versus-leukemia | Q38659485 | ||
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. | Q38700150 | ||
GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. | Q38727251 | ||
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models | Q38736457 | ||
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes | Q38852431 | ||
Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival | Q39037263 | ||
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. | Q40843566 | ||
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects | Q40936847 | ||
A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice | Q41627096 | ||
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models | Q41865091 | ||
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. | Q45301087 | ||
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. | Q45301393 | ||
Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis | Q45851521 | ||
P433 | issue | 8 | |
P304 | page(s) | 1516-1530 | |
P577 | publication date | 2018-11-12 | |
P1433 | published in | Cell Death & Differentiation | Q2943974 |
P1476 | title | Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes | |
P478 | volume | 26 |
Q92540859 | Impacts of exercise interventions on different diseases and organ functions in mice | cites work | P2860 |
Search more.